Drug Trial Radar · NCT07499440
Safety and Efficacy of HB-1 for Post-Traumatic Stress Disorder
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jun 3, 2026
Primary completion
Sep 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- HB BioTech, LLCIndustry
- Sponsor type
- Industry
- First posted
- Mar 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety and efficacy of HB-1, versus placebo in male and female adult patients aged 18 to 65 years, inclusive, with Post-Traumatic Stress Disorder (PTSD).
Conditions
- PTSD
- Mental Illness
Interventions
HB-1Drug
HB-1 will be supplied as a dual active pharmaceutical ingredient tablet. The two HB-1 doses for this study include 64/192 and 86/258 telmisartan/verapamil extended release, using unique bi-layer tablets. All subjects randomized to receive HB-1 will begin with the 64/192mg dose taken as one tablet once per day. At each monthly visit, treatment tolerance and response will be adjudicated using objective, dose-escalation criteria. At both Week 4 and Week 8, all subjects will be evaluated for dose escalation. Subjects who are demonstrating a reduction of 50% or more in CAPS-5 total score will remain in treatment with HB-1 (or Placebo) at same dose. Subjects with less than a 50% reduction in CAPS-5, who have experienced no treatment-emergent Grade 3 or higher adverse event related to study drug since the prior visit, will be dose-escalated to the 86/258mg telmisartan/verapamil extended dose. After escalation, subjects will remain on higher dose throughout the remainder of the study.
PlaceboDrug
Matching Placebo will be dispensed to analogous subjects in Placebo group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To measure the efficacy of HB-1 on clinician-rated symptoms of Post-Traumatic Stress Disorder in male and female adults (age 18 to 65 years) with Post-Traumatic Stress Disorder.Time frame: Baseline, Week 4, Week 8 and Week 12.
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Paratus Clinical Research Canberra
Deakin, Australian Capital Territory, Australia · Recruiting
Novatrials
Charlestown, New South Wales, Australia · Recruiting
East Sydney Doctors
Darlinghurst, New South Wales, Australia · Recruiting
Innovate Clinical Research
Waitara, New South Wales, Australia · Recruiting
WSLHD Mental Health Services, Westmead Hospital
Westmead, New South Wales, Australia · Recruiting
Paratus Clinical Research Brisbane
Herston, Queensland, Australia · Recruiting
Mackay Hospital and Health Service
Mackay, Queensland, Australia · Recruiting
University of the Sunshine Coast Clinical Trials, Morayfield
Morayfield, Queensland, Australia · Recruiting
Ramsay Clinic New Farm
New Farm, Queensland, Australia · Recruiting
University of the Sunshine Coast Clinical Trials, Sippy Downs
Sippy Downs, Queensland, Australia · Recruiting
South Australian Health and Medical Research Institute
Adelaide, South Australia, Australia · Recruiting
NeuroCentrix
Carlton, Victoria, Australia · Recruiting
Peninsula Therapeutic and Research Group
Frankston, Victoria, Australia · Recruiting
Monash Alfred Psychiatry Research Centre
Melbourne, Victoria, Australia · Recruiting
Ramsay Clinic Albert Road
Melbourne, Victoria, Australia · Recruiting
Paratus Clinical Research Melbourne
Northcote, Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.